

10/562470

IAP15 Rec'd PCT/PTO 22 DEC 2005

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Philippe G. Nantermet	
Serial No.:	To Be Assigned	Case No.: 21456YP
US Nat'l Filing Date:	December 22, 2005	
Int'l Appl'n No.	PCT/US2004/020525	
Int'l Filing Date:	25 June 2004	
For:	PHENYLCARBOXYLATE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE	

Commissioner for Patents
P.O. BOX 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR § 1.97

Sir:

In compliance with 37 CFR § 1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO-1449, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of each reference.

EXPRESS MAIL CERTIFICATE

DATE OF DEPOSIT December 22, 2005
EXPRESS MAIL NO. EX1625845

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail "Post Office to Addressee" on the above date in an envelope addressed to:

Commissioner for Patents, P. O. Box 1450,
Alexandria, Virginia 22313-1450

MAILED BY Lori Schepisi
DATE 12-22-05

This Information Disclosure Statement is not an admission that any patent, publication, or other information referred to herein is "prior art" for this invention.

In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b). In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.


References BB, CC, DD and EE were cited in the International Search Report during the International phase of this application. A copy of the International Search Report and Written Opinion of the International Searching Authority are enclosed.

Reference BB is an abstract of reference E; reference CC is an abstract of reference D; and reference DD is an abstract of reference C.

Pursuant to 37 CFR § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the present application. Accordingly, it is believed that no fee is due.

Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

Respectfully submitted,

By 
John C. Todaro, Reg. No. 36,036
Attorney for Applicant

MERCK & CO., Inc.
P.O. Box 2000
Rahway, New Jersey 07065-0907
(732) 594-0125

Date: December 22, 2005

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				COMPLETE IF KNOWN	
				Application Number	To Be Assigned 10/562470
				Filing Date	December 22, 2005
				First Named Inventor	Philippe G. Nantermet
				Group Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
				Attorney Docket Number	21456YP
Sheet	1	of	2		

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
	A		WO 89/04833	PCT	The Upjohn Company	06/01/1989
	B		WO 01/00665	PCT	Oklahoma Medical Research Foundation &	01/04/2001
					The Board of Trustees of the	
					University of Illinois	
	C		WO 2003/072535	PCT	Elan Pharmaceuticals, Inc.	09/04/2003
					& Pharmacia & Upjohn	
	D		EP 1 186 305	PCT	Schering Aktiengesellschaft	03/13/2002
	E		JP 02000129	PCT	Fujisawa	05/01/1990
	F		WO 03/106405	PCT	Sunesis Pharmaceuticals, Inc.	12/24/2003
	G		WO 2005/0053374	PCT	Sunesis Pharmaceuticals, Inc.	01/20/2005

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005

Substitute for form 1449B/PTO

STATEMENT BY APPLICANT

(use as many sheets as necessary)

COMPLETE IF KNOWN**Application Number**

To Be Assigned

101562470

December 22, 2005

Philippe G. Nantermet

To Be Assigned

To Be Assigned

Sheet

2

of

2

Attorney Docket Number

21456YP

NON PATENT LITERATURE DOCUMENTS

Examiner
Initials*Cite
No.

Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.

AA

C. A. Coburn et al., "Identification of a Small Molecule Nonpeptide Active Site Beta-Secretase Inhibitor That Displays a Nontraditional Binding Mode for Aspartyl Proteases," J. Med. Chemistry, Vol. 47, pp. 6117-6119 (2004)

BB

E. Rubini et al., "Synthesis of Isosteric Methylene-Oxy Pseudodipeptide Analogues As Novel Amide Bond Surrogate Units," *Tetrahedron*, Vol. 42, No. 21, pp. 6039-6045 (1986)

CC

CAPLUS Abstract 113:40174

DD

CAPLUS Abstract 139:230480

EE

CAPLUS Abstract 136:232115

Examiner
SignatureDate
Considered